IMNN
Imunon IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$10.83M
P/E Ratio
—
EPS
$-6.83
Beta
2.03
52W High
$35.84
52W Low
$2.52
50-Day MA
$2.99
200-Day MA
$4.24
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
16.78
PEG Ratio
5.03
About Imunon Inc
Imunon Inc. is a clinical-stage biotechnology firm focused on pioneering immune-mediated therapies aimed at combating cancer and infectious diseases. Utilizing its proprietary INFECT platform, the company is dedicated to enhancing immune responses that facilitate the effective eradication of malignancies. With a robust pipeline of therapeutics in various stages of clinical evaluation and strategic collaborations that bolster its research capabilities, Imunon is well-positioned to drive notable advancements in immunotherapy, ultimately transforming patient care and establishing a competitive foothold in the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | 125,000 |
| Gross Profit (TTM) | $2.72M |
| EBITDA | $-14.36M |
| Operating Margin | 0.00% |
| Return on Equity | -256.40% |
| Return on Assets | -83.20% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $2.06 |
| Price-to-Book | 1.54 |
| Price-to-Sales (TTM) | 17.94 |
| EV/Revenue | 4.004 |
| EV/EBITDA | 0.91 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $3.98M |
| Float | $3.54M |
| % Insiders | 0.65% |
| % Institutions | 10.82% |
Historical Volatility
HV 10-Day
36.20%
HV 20-Day
38.11%
HV 30-Day
45.74%
HV 60-Day
42.97%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($19.20 target)
3
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/11/2026